Benefits of the MAB Discovery Process:

Two species of wild type animals are available for immunization

  • Use of wild type vs genetically modified yields maximum diversity
  • The two repertoires complement one another to add even greater epitope coverage
  • Rabbit derived monoclonals are particularly potent (pM) and require no further affinity optimization
  • Use of rabbit derived monoclonals is validated in the clinic

Individual B cells are cloned and screened

  • Retains original VH/VL combination that originally arose via the natural process
  • Fully automated process

Explores unique diversity by capturing monoclonals at different stages of maturation

  • Several bleeds per animal

Allows to discover the "rare event" specificity

High degree in automation results in speed and overall efficiency